Global Artificial Organ Market Size, Share, Opportunities, And Trends By Product Type (Artificial Heart, Artificial Kidney, Artificial Lungs, Artificial Liver, Artificial Pancreas, Cochlear Implants, Other Types), By Organ Type (Permanent Artificial Organs, Temporary Artificial Organs), And By Geography - Forecasts From 2025 To 2030

Artificial Organ Market Size and Forecast:

The global artificial organ market is set to witness robust growth at a CAGR of 7.35% during the forecast period to be worth US$6.687 billion in 2030 from US$4.691 billion in 2025.

Artificial Organ Market Trends:

Several trends are driving the global artificial organs market growth, including 3D printers, nanotechnology, and advanced AI. These technologies make organs with patient-specific structures with a high level of complexity and biocompatibility. Nanomaterials are constantly integrated to improve the performance and durability of the product. AI is applied in organ design, and its functionality is integrated with patient needs for better treatment application and a higher success rate. The lack of organ donors is encouraging patients waiting for a transplant to use artificial organs, increasing its popularity in the future.

Artificial Organ Market Growth Drivers:

• Increasing prevalence of chronic diseases: The market for artificial organs worldwide is rising because the population requires more treatment solutions due to the rising incidence of chronic illnesses. These devices present a possible approach to patients with organ dysfunction, serving as temporary support to organ transplantation or lifelong replacement. Heart disease, cancer, stroke, chronic lower respiratory diseases, and diabetes are the leading causes of death in America, with statistics showing 702,880 deaths, 608,371, 165,393 deaths, 147,382 deaths, and 101,209 deaths, respectively, in 2023.
• Rising Aging Population: The current aging global population boosts the development of the artificial organ market caused by diseases such as cardiovascular, kidney, respiratory, and neurodegenerative diseases and declined organ functions during the aging process, resulting in organ failure arising from the natural aging process.

The number of US Americans aged 50 and older will increase by 61.11% from 137.25 million in 2020 to 221.13 million by 2050, and chronic illness will increase by 99.5%, from 71.522 million in 2020 to 142.66 million in 2050.

Artificial Organ Market Segmentation Analysis by Product Type:

• Artificial Heart: An upsurge in heart failures, particularly due to lifestyle-induced changes and an aging population, has increased the demand for artificial hearts. This is coming with the rise in technological advances and less invasive surgical techniques that are giving rise to the adoption of smaller, more durable, and enhanced artificial heart implants.
• Artificial Kidney: With the lack of organ donors and chronic kidney diseases like diabetes and hypertension, artificial kidney implants are becoming increasingly in demand.
• Artificial Lungs:  The product type has been driven majorly due to increasing respiratory diseases like COPD and lung cancer. Advancements in extracorporeal membrane oxygenation (ECMO) technology work to improve patient outcomes and expand use across critical care settings.

Artificial Organ Market Segmentation Analysis by Organ Type:

• Permanent Artificial Organs: Permanent artificial organs are designed to cover organ failures permanently, hence an enduring solution for the escalating demand in end-stage organ failure patients.
• Temporary Artificial Organs:  These organ types will witness a rise with the advancements in mobility and ease of use. Compact and easy-to-use temporary artificial organs are slowly gaining traction in intensive care settings.

Artificial Organ Market Geographical Outlook:

The global artificial organ market report analyzes growth factors across the following five regions:

• North America:  High healthcare infrastructure, increased adoption of advanced technologies, and vast patient pool make North America the dominant market player. For example, healthcare expenses increased by 7.5% to $4.9 trillion in 2023, reaching 14,570 per person.
• South America: The South American region is on the rise in sales of artificial organ products. With the rapid incidence of chronic diseases, reduced awareness, and improved infrastructure in the health sector, the region is slowly creating brand equity in the artificial organ sector.
• Europe: Europe is well known for using artificial organs due to the aging population and a robust healthcare system backed by government initiatives emphasizing investigation, innovative technologies, and developments. The region will see a drastic rise from the 90.5 million older population in 2019 to reach 129.8 million in about 30 years, i.e., by 2050.
• Middle East and Africa:  The emergence of a strong artificial organ market in the MEA regions will largely be driven by health infrastructural investments, increasing government funding, and the government's efforts at enhancing healthcare access.
• Asia-Pacific: The Asia-Pacific region is anticipated to experience significant growth in the artificial organ market due to economic transformations. This growth is driven by the increasing prevalence of chronic diseases among the aging population, rising government expenditures on healthcare facilities, and improvements in public awareness.

Artificial Organ Market– Competitive Landscape:

• Abiomed
• Asahi Kasei Medical Co. Ltd.
• Baxter
• Boston Scientific Corporation
• Medtronic

Positive changes are observed in the market as major companies develop new technologies and introduce innovative products. This is leading to higher competition among already established players and new companies being attracted to the field. However, based on the present scenario, established leaders are still predicted to be the major contributors to market growth.

Artificial Organ Market Latest Developments:

• In December 2024, BiVACOR reported the insertion of its BiVACOR Total Artificial Heart (TAH) into five patients in the presence of an FDA Early Feasibility Study. The results are proven to be safe and effective in bridging the gap till a standard donor heart transplant. This appears to promote expanding its EFS to twenty patients.
• In December 2024, United Therapeutics inaugurated the transplantation of the world's first Ukidney in the company of a living transplant after successfully conducting UHeart™ and UThymoKidney™ within three living recipients.

Artificial Organ Market Scope:

Report Metric	Details
Artificial Organ Market Size in 2025	US$4.691 billion
Artificial Organ Market Size in 2030	US$6.687 billion
Growth Rate	CAGR of 7.35%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Billion
Segmentation	Product Type Organ Type Geography
Geographical Segmentation	North America, South America, Europe, Middle East and Africa, Asia Pacific
List of Major Companies in the Artificial Organ Market	Baxter Boston Scientific Corporation Asahi Kasei Medical Medtronic PLC Abiomed
Customization Scope	Free report customization with purchase

 

Artificial Organ Market is analyzed into the following segments:

• By Product Type
  • Artificial Heart
  • Artificial Kidney
  • Artificial Lungs
  • Artificial Liver
  • Artificial Pancreas
  • Cochlear Implants
  • Other Types
• By Organ Type
  • Permanent Artificial Organs
  • Temporary Artificial Organs
• By Geography
  • North America
    • USA
    • Canada              
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Others

Our Best-Performing Industry Reports:

• AI In MRI Market
• Healthcare Artificial Intelligence Market
• Biomimetic Materials Market

---

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

2.1. Research Design

2.2. Research Process

3. EXECUTIVE SUMMARY

3.1. Key Findings

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5.  GLOBAL ARTIFICIAL ORGAN MARKET BY PRODUCT TYPE 

5.1. Introduction

5.2. Artificial Heart

5.3. Artificial Kidney

5.4. Artificial Lungs

5.5. Artificial Liver

5.6. Artificial Pancreas

5.7. Cochlear Implants

5.8. Other Types

6. GLOBAL ARTIFICIAL ORGAN MARKET BY ORGAN TYPE 

6.1. Introduction

6.2. Permanent Artificial Organ

6.3. Temporary Artificial Organ

7. GLOBAL ARTIFICIAL ORGAN MARKET BY GEOGRAPHY

7.1. Introduction

7.2. North America

7.2.1. By Product Type

7.2.2. By Organ Type

7.2.3. By Country

7.2.3.1. USA

7.2.3.2. Canada

7.2.3.3. Mexico

7.3. South America

7.3.1. By Product Type

7.3.2. By Organ Type

7.3.3. By Country

7.3.3.1. Brazil

7.3.3.2. Argentina

7.3.3.3. Others

7.4. Europe

7.4.1. By Product Type

7.4.2. By Organ Type

7.4.3. By Country

7.4.3.1. United Kingdom

7.4.3.2. Germany

7.4.3.3. France

7.4.3.4. Spain

7.4.3.5. Others

7.5. Middle East and Africa

7.5.1. By Product Type

7.5.2. By Organ Type

7.5.3. By Country

7.5.3.1. Saudi Arabia

7.5.3.2. UAE

7.5.3.3. Others

7.6. Asia Pacific

7.6.1. By Product Type

7.6.2. By Organ Type

7.6.3. By Country

7.6.3.1. China

7.6.3.2. Japan

7.6.3.3. India

7.6.3.4. South Korea

7.6.3.5. Taiwan

7.6.3.6. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

8.1. Major Players and Strategy Analysis

8.2. Market Share Analysis

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Competitive Dashboard

9. COMPANY PROFILES

9.1. Baxter

9.2. Boston Scientific Corporation

9.3. Asahi Kasei Medical

9.4. Medtronic PLC

9.5. Abiomed

9.6. SynCardia Systems

9.7. Carmat

9.8. Getinge

9.9. Terumo

9.10. BiVACOR Inc

Baxter

Boston Scientific Corporation

Asahi Kasei Medical

Medtronic PLC

Abiomed

SynCardia Systems

Carmat

Getinge

Terumo

BiVACOR Inc